A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy
Lung Cancer, Tuberculosis, Sarcoidosis
About this trial
This is an interventional treatment trial for Lung Cancer focused on measuring bronchoscopy, lignocaine, cough
Eligibility Criteria
Inclusion Criteria:
- Consecutive patients undergoing flexible bronchoscopy
- Hemodynamic stability
Exclusion Criteria:
- Patients receiving sedatives during the course of their treatment
- Patients undergoing conventional TBNA and/or EBUS-TBNA who are likely to receive sedation
- Patients with known hypersensitivity to lignocaine
- Not willing to provide informed consent
Sites / Locations
- Bronchoscopy suite, PGIMER
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
1% lignocaine
2% lignocaine
Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (1%) 8ml will be administered as "spray as you go" technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients.
Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (2%) 8ml will be administered as "spray as you go" technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients.